- Company will explore strategic alternatives for its immuno-oncology programs
- Company will align its resources to focus on HEPLISAV-B commercialization
- Eddie Gray, CEO, to retire
BERKELEY, Calif., May 23, 2019 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ: DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the companys first commercial product HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]. As part of the restructuring, the company will explore strategic alternatives for its immuno-oncology portfolio and will reduce the companys workforce and operations to focus resources on HEPLISAV-B commercialization. While the companys near-term focus will be on HEPLISAV-B sales…
Read the full article at: https://globenewswire.com/news-release/2019/05/23/1841968/0/en/Dynavax-Announces-Strategic-Restructuring-to-Focus-on-its-Vaccine-Business.html